| Joana Silva, FNP | |
|
2935 Sw Cedar Hills Blvd, Beaverton, OR 97005-1342 | |
| (503) 352-6000 | |
| (503) 352-6080 |
| Full Name | Joana Silva |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 2935 Sw Cedar Hills Blvd, Beaverton, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538583471 | NPI | - | NPPES |
| 500667754 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 201394045NP (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence St Vincent Medical Center | Portland, OR | Hospital |
| Providence Milwaukie Hospital | Milwaukie, OR | Hospital |
| Providence Willamette Falls Medical Center | Oregon city, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Oregon | 0648183608 | 1328 |
News Archive
American Heart Association (AHA) President Robert A. Harrington says that the life expectancy has gone up in recent years. Still, he points out, improved life expectancy doesn't translate to improved health in all cases. According to him, "Not all those years are healthy ones as the effects of chronic illnesses are increasingly impacting the quality of life of people at a much younger age than in the past."
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
As Republicans and Democrats on the congressional super committee swapped plans to reduce the federal deficit, the ideas they advanced demonstrated that the parties remain at odds over increasing taxes and making deep spending cuts to Medicare and Medicaid.
Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
› Verified 1 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
American Heart Association (AHA) President Robert A. Harrington says that the life expectancy has gone up in recent years. Still, he points out, improved life expectancy doesn't translate to improved health in all cases. According to him, "Not all those years are healthy ones as the effects of chronic illnesses are increasingly impacting the quality of life of people at a much younger age than in the past."
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
As Republicans and Democrats on the congressional super committee swapped plans to reduce the federal deficit, the ideas they advanced demonstrated that the parties remain at odds over increasing taxes and making deep spending cuts to Medicare and Medicaid.
Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
› Verified 1 days ago
| Entity Name | Virginia Garcia Memorial Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679528012 PECOS PAC ID: 7113823881 Enrollment ID: O20031211000992 |
News Archive
American Heart Association (AHA) President Robert A. Harrington says that the life expectancy has gone up in recent years. Still, he points out, improved life expectancy doesn't translate to improved health in all cases. According to him, "Not all those years are healthy ones as the effects of chronic illnesses are increasingly impacting the quality of life of people at a much younger age than in the past."
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
As Republicans and Democrats on the congressional super committee swapped plans to reduce the federal deficit, the ideas they advanced demonstrated that the parties remain at odds over increasing taxes and making deep spending cuts to Medicare and Medicaid.
Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
› Verified 1 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568547503 PECOS PAC ID: 5294623245 Enrollment ID: O20040310000315 |
News Archive
American Heart Association (AHA) President Robert A. Harrington says that the life expectancy has gone up in recent years. Still, he points out, improved life expectancy doesn't translate to improved health in all cases. According to him, "Not all those years are healthy ones as the effects of chronic illnesses are increasingly impacting the quality of life of people at a much younger age than in the past."
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
As Republicans and Democrats on the congressional super committee swapped plans to reduce the federal deficit, the ideas they advanced demonstrated that the parties remain at odds over increasing taxes and making deep spending cuts to Medicare and Medicaid.
Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
› Verified 1 days ago
| Entity Name | Icco Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407004757 PECOS PAC ID: 1355406729 Enrollment ID: O20090218000510 |
News Archive
American Heart Association (AHA) President Robert A. Harrington says that the life expectancy has gone up in recent years. Still, he points out, improved life expectancy doesn't translate to improved health in all cases. According to him, "Not all those years are healthy ones as the effects of chronic illnesses are increasingly impacting the quality of life of people at a much younger age than in the past."
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
As Republicans and Democrats on the congressional super committee swapped plans to reduce the federal deficit, the ideas they advanced demonstrated that the parties remain at odds over increasing taxes and making deep spending cuts to Medicare and Medicaid.
Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
› Verified 1 days ago
| Entity Name | Express Care Or Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205499126 PECOS PAC ID: 1254768732 Enrollment ID: O20200311001372 |
News Archive
American Heart Association (AHA) President Robert A. Harrington says that the life expectancy has gone up in recent years. Still, he points out, improved life expectancy doesn't translate to improved health in all cases. According to him, "Not all those years are healthy ones as the effects of chronic illnesses are increasingly impacting the quality of life of people at a much younger age than in the past."
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
As Republicans and Democrats on the congressional super committee swapped plans to reduce the federal deficit, the ideas they advanced demonstrated that the parties remain at odds over increasing taxes and making deep spending cuts to Medicare and Medicaid.
Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
› Verified 1 days ago
| Entity Name | Amg Of Oregon Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407443112 PECOS PAC ID: 7911310719 Enrollment ID: O20210707003069 |
News Archive
American Heart Association (AHA) President Robert A. Harrington says that the life expectancy has gone up in recent years. Still, he points out, improved life expectancy doesn't translate to improved health in all cases. According to him, "Not all those years are healthy ones as the effects of chronic illnesses are increasingly impacting the quality of life of people at a much younger age than in the past."
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
As Republicans and Democrats on the congressional super committee swapped plans to reduce the federal deficit, the ideas they advanced demonstrated that the parties remain at odds over increasing taxes and making deep spending cuts to Medicare and Medicaid.
Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joana Silva, FNP Po Box 568, Cornelius, OR 97113-0568 Ph: (503) 352-8657 | Joana Silva, FNP 2935 Sw Cedar Hills Blvd, Beaverton, OR 97005-1342 Ph: (503) 352-6000 |
News Archive
American Heart Association (AHA) President Robert A. Harrington says that the life expectancy has gone up in recent years. Still, he points out, improved life expectancy doesn't translate to improved health in all cases. According to him, "Not all those years are healthy ones as the effects of chronic illnesses are increasingly impacting the quality of life of people at a much younger age than in the past."
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
As Republicans and Democrats on the congressional super committee swapped plans to reduce the federal deficit, the ideas they advanced demonstrated that the parties remain at odds over increasing taxes and making deep spending cuts to Medicare and Medicaid.
Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
› Verified 1 days ago
Amanda Hunt, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4145 Sw Watson Ave Ste 350, Beaverton, OR 97005 Phone: 866-849-0692 | |
Mrs. Sherry Diane Davidson, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 10700 Sw Beaverton-hillsdale Hwy, Park Plaza West Bld 3 Suite 547, Beaverton, OR 97005 Phone: 503-643-0428 | |
Dr. Kathleen Anne Roberts, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2725 Sw Cedar Hills Blvd Ste 200, Beaverton, OR 97005 Phone: 503-352-6000 Fax: 503-352-6081 | |
Sherry L Sweeney, CPNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 15455 Nw Greenbrier Pkwy, Suite 111, Beaverton, OR 97006 Phone: 503-531-2323 | |
Ms. Hillary L Corson, APRN, PMHNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6600 Sw 105th Ave Ste 120, Beaverton, OR 97008 Phone: 971-245-1332 Fax: 503-641-5179 | |
Ms. Victoria Lynn Keyton, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4510 Sw Hall Blvd, Beaverton, OR 97005 Phone: 503-644-1171 Fax: 503-643-7443 | |
Margie Nielsen, DNP, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 15950 Sw Millikan Way, Beaverton, OR 97003 Phone: 503-646-0161 Fax: 503-643-7459 |